Trial | NCT00038428  Report issue

Title

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    tlk286 ...

  • Study Participants

    40
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
Study Started
Jun 30
2001
Primary Completion
Jul 31
2005
Study Completion
Jul 31
2005
Last Update
Jul 25
2011
Estimate

Drug TLK286

Criteria 

Inclusion Criteria

Histologic diagnosis of ovarian cancer
Recurrent or persistent disease following primary therapy
Measurable disease
Prior treatment with at least one but no more than three prior chemotherapy regimens
Resistant or refractory to platinum-based chemotherapy
At least 18 years of age
Good performance status (ECOG 0 to 1)
Adequate liver, renal and bone marrow function

Exclusion criteria

Pregnant or currently breast feeding
Treatment with chemotherapy or immunotherapy within four weeks
Prior radiation to the whole pelvis
No Results Posted